Session 122 - 12th CROI

Home

Session 122 Poster Abstracts
Resistance to Specific Drugs and Drug Combinations
Friday, 1:30 - 3:30 pm
Hall A

713	Comparison of the Phenotypic Effects of NRTI Mutations on Emtricitabine and Lamivudine Lisa Ross*¹, N Parkin², M Underwood¹, P Gerondelis¹, M St Clair¹, and E Lanier¹ ¹GlaxoSmithKline, Research Triangle Park, NC, USA and ²ViroLogic, Inc, South San Francisco, CA, USA
714	Cross-resistance of Clinical Samples with K65R, L74V, and M184V Mutations Mark Underwood*¹, M St Clair¹, L Ross¹, P Gerondelis¹, N Parkin², and R Lanier¹ ¹GlaxoSmithKline, Research Triangle Park, NC, USA and ²ViroLogic, Inc, South San Francisco, CA, USA
715	Synergistic Activity of Atazanavir and Saquinavir on Viruses with Low Saquinavir and High Atazanavir Resistance S Lebel-Binay¹, L Thibaut¹, E Dam¹, J L Faudon¹, Arnaud Chéret*¹, A Hill², and F Clavel³ ¹Viralliance, Paris, France; ²Roche, UK; and ³INSERM U552, Hosp Bichat-Claude Bernard, Paris, France
716	Atazanavir Resistance in a Protease Inhibitor-naïve Patient Treated with Atazanavir/Ritonavir Associated with Development of High-level Atazanavir Resistance and the N88S Mutation in Protease Eoin Coakley*¹, M Mass², and N Parkin¹ ¹ViroLogic, Inc, South San Francisco, CA, USA and ²private practice, San Francisco, CA, USA
717	Rapid Selection of High-level Resistance to Enfuvirtide Laura Maroldo*, E Coakley, C Chappey, S Fransen, J Toma, J Whitcomb, W Huang, and C Petropoulos ViroLogic, Inc, South San Francisco, CA, USA
718	Genotypic Evolution of T-20 Resistance-associated Mutations in Heavily Treated HIV-infected Patients on Long-term Treatment with T-20 Cecilia Cabrera*¹, E Garcia¹, S Marfil¹, J Martínez-Picado¹, A Bonjoch², E Grau¹, C Gutiérrez³, M Pérez-Elías³, S Moreno³, B Clotet⁴, and L Ruiz¹ ¹IrsiCaixa Fndn, Barcelona, Spain; ²Lluita contra la SIDA Fndn, Barcelona, Spain; ³Hosp Ramón y Cajal, Univ de Alcalá de Henares, Madrid, Spain; and ⁴IrsiCaixa Fndn and Lluita contra la SIDA Fndn, Barcelona, Spain
719	Virological Response and Resistance to Lopinavir/Ritonavir in Subtype-C Patients Zehava Grossman*¹, M Lorber², L Thibaut³, E Shahar², D Torten⁴, I Levy⁵, K Riesenberg⁶, M Chowers⁷, V Istomin⁸, D Averbuch⁹, Z Kra-Oz², S Pollack², S Maayan⁹, J Faudon³, J Schapiro⁵, and The Israeli Multi Center AIDS Study Group ¹Natl HIV Reference Lab, PHL, MOH, Ramat Gan, Israel; ²Rambam Med Ctr, Haifa, Israel; ³Viralliance, Paris, France; ⁴Kaplan Med Ctr, Rehovot, Israel; ⁵Sheba Med Ctr, Ramat Gan, Israel; ⁶Soroka Med Ctr, Beer Sheva, Israel; ⁷Meir Med Ctr, Kfar Saba, Israel; ⁸Hillel Yaffe Med Ctr, Hadera, Israel; and ⁹Hadassah Med Ctr, Jerusalem, Israel
720	Clonal Analysis of Week 12 Virologic Non-responders Receiving Tenofovir/Abacavir/Lamivudine in ESS30009 E Rouse¹, Peter Gerondelis*¹, D Paulsen¹, M Underwood¹, D McClernon¹, L Preble¹, J McCarville¹, M Lim¹, M Shaefer¹, A Rodriguez², J Gallant³, Q Liao¹, R Lanier¹, and L Ross¹ ¹GlaxoSmithKline, Research Triangle Park, NC, USA; ²Univ of Miami, FL, USA; and ³Johns Hopkins Univ, Baltimore, MD, USA
721	Baseline Genetic Drug Resistance Analysis of South African HIV-1 Subtype C Proteases Pascal Bessong*¹, J Mphahlele², L Obi³, D Rekosh¹, and M L Hammerskjold¹ ¹Univ of Virginia, Charlottesville, USA; ²Med Univ of Southern Africa, Pretoria; and ³Univ of Venda, Thohoyandou, South Africa